THE SIGNAL THROUGH THE NOISE

THROUGH THE NOISE



The Biological Reality of ApoB and the Organized Denial of Cholesterol Science

Atherosclerotic cardiovascular disease remains the leading global cause of mortality

The Signal

Biochemistry

Mendelian Randomization

170,000+ Patient Trials

ApoB-containing lipoproteins drive plaque progression

The Noise

This document dismantles the denialism to reveal the biological supremacy of the ApoB-particle hypothesis.

The mechanism of atherosclerosis is driven by particle count, not cholesterol mass

Standard LDL-C (Mass)

- Traditional LDL-C measures the weight of cholesterol.

ApoB (Particle Number)

- Every atherogenic particle (VLDL, IDL, LDL, Lp[a]) contains exactly one molecule of ApoB-100.

Mechanistic Reality: Individuals with metabolic syndrome often have small, dense, cholesterol-depleted LDL. A “normal” LDL-C of 100 mg/dL can mask a fatally elevated ApoB particle fleet.

Subendothelial entrapment is a function of concentration gradients, not just inflammation.



The Claim:
Metabolic health (high HDL, low triglycerides) neutralizes LDL risk.

The Reality: The biological mechanism does not require metabolic dysfunction. **It only requires a sufficient ApoB concentration gradient across the endothelial barrier. Entrapment is driven by physics.**

The Diagnostic Matrix (LDL-C vs. ApoB)

UK Biobank NMR sub-study data (n=375,544)

Discordance Category	Risk of MACE (Hazard Ratio)	Clinical Interpretation
Concordant (LDL-C & ApoB match)	1.0 (Referent)	Standard Risk Assessment.
Discordantly High ApoB (Low LDL-C, High ApoB)	**1.11**	**Risk under-estimated** by LDL-C.
Discordantly Low ApoB (High LDL-C, Low ApoB)	0.87	Risk **over-estimated** by LDL-C.

Mediated by VLDL & Triglycerides - 25.5% & 26.6%

Takeaway:

When ApoB and LDL-C are discordant, cardiovascular risk tracks exclusively with the ApoB particle count, rendering traditional lipid panels dangerously incomplete for metabolic dysfunction.

PCSK9 Variants:
Lifelong lower LDL-C yields a 54% reduction in CHD risk per 38.7 mg/dL reduction.

NPC1L1 Variants:
Mimics ezetimibe, reducing risk proportionally to LDL-C lowering.

LPA Locus:
Genetically elevated Lp(a) is an independent causal risk factor for ASCVD and aortic stenosis.

Mendelian randomization (MR) uses the random allocation of genetic alleles at conception to study lifetime exposure. It is immune to the confounding, reverse causation, and lifestyle factors that plague observational studies.

Cardiovascular Risk Reduction

The compounding mathematics of lipoprotein-years.

CHD Risk Reduction per 38.7 mg/dL LDL-C Reduction		
Mechanism	**MR Estimate (Lifetime Genetics)**	**RCT Estimate (Short-Term Trials)**
HMGCR (Statin target)	~54.5%	~22% (5-Year)
PCSK9 (Evolocumab target)	~54.5%	~15% (2.2-yr follow up)
NPC1L1 (Ezetimibe target)	~54.5%	~15% (7-yr as add-on)

Takeaway:

Genetic studies reveal a 3x greater benefit than clinical trials.
Why? Because atherosclerosis is driven by exposure time. Lowering lipids early prevents initiation; lowering them at age 60 is merely damage control on pre-existing plaque.

The Pleiotropy Myth: Risk reduction is strictly proportional to lipid lowering.



Debunking Pleiotropy:
Critics claim statins work via independent anti-inflammatory mechanisms.

Yet, Ezetimibe (no anti-inflammatory activity) and PCSK9 inhibitors (used in patients with already suppressed inflammation) produce cardiovascular event reductions that fall exactly on the statin regression line.

Benefit is derived purely from lowering the ApoB burden.

Reconciling historical anomalies within the lipid model



The Inuit Paradox

The claim of immunity from a high-fat marine diet rested on fragile mortality statistics and garbage codes. Modern standardization and 1960s autopsy data confirm atherosclerosis is common in Inuit populations, directly tracking with LDL-C and ApoB.

The French Paradox

Low CHD rates despite high saturated fat intake in the 1990s were an illusion of time-lag. French animal fat consumption only reached Western norms in the late 1960s. Since atherosclerosis takes decades to manifest, 1990s mortality reflected mid-century lower lipid levels.

Survivor bias and the failure of HDL therapeutics



The FH “Healthy Survivor”

Heterozygous FH carries a 20-fold risk of premature CAD. Unmedicated 80-year-old survivors are explained by selection bias, protective genetic modifiers (loss-of-function PCSK9 variants), and an absence of risk multipliers (smoking, hypertension). They are the exception, not the rule.

The HDL Paradox

Raising HDL via CETP inhibitors or niacin completely failed to reduce cardiovascular risk. HDL is a marker of favorable metabolic health, not a causal maker of risk. Conversely, every therapy that lowers ApoB proportionally reduces risk.

The Lean Mass Hyper-Responder (LMHR) Question

Context:

Lean individuals on ketogenic diets who experience extreme LDL-C spikes (>200 mg/dL).

Skeptics use the KETO-CTA 12-month pilot study to claim low risk.



The Scientific Reality:

Plaque progression typically takes decades to manifest in healthy individuals.

Falsifying the lipid hypothesis requires a lifetime of extreme LDL exposure without plaque formation.

The Critical Caveat:

In the KETO-CTA study itself, while ApoB didn't predict progression within a brief 1-year window, baseline plaque burden did predict progression—confirming that existing atherosclerosis remains highly vulnerable to high lipids.

The origins of the noise: A historical false dichotomy

1965

Project 226 - Sugar Research Foundation pays Harvard scientists $50k to exonerate sucrose and blame dietary fat.

1980s-90s

The Fat vs. Sugar False Dichotomy takes root in public consciousness.

2007–2016

Gary Taubes publishes works leveraging the Ancel Keys epidemiological debate to claim the entire lipid hypothesis is corrupt.

Present Day

Heterodox figures exploit this history to justify modern ApoB denialism.



Heterodox figures exploit this history to justify modern ApoB denialism.

Takeaway: The legitimate historical debate over dietary fat and sugar epidemiology has been rhetorically weaponized to dismiss the entirely separate, modern proof of ApoB-lipoprotein causality.

Commodity Industry Interference: Manufacturing Scientific Uncertainty

Egg Industry (2010-2019):

Funded 60% of research on eggs and cholesterol.

While 86% of studies proved eggs raise LDL-C, industry-**funded papers reported** discordant conclusions, **claiming the increases were "not clinically significant."**

UNCERTAINTY

Dairy & Meat Industries:

Deployed the NutriRECS systematic reviews.

By using GRADE methodology—designed for short-term pharma RCTs—they classified all long-term **dietary cohort evidence as "low certainty."**

The Tactic: Technically defensible on narrow methodological grounds, but operationally deployed to dismiss consistent risk signals and maintain current high-meat dietary market shares.

The Architecture of Commercial Denialism



The Core Logic: Guidelines limiting saturated fat restrict massive commercial markets. By promoting the narrative that saturated fat is harmless and ApoB is irrelevant, these industries simultaneously expand sales and cultivate an ideologically committed consumer base that views scientific consensus as corruption.

Deconstructing the Commercial Ecosystem's Claims

The Paleo Ancestral Immunity Claim

The Horus study of CT imaging in mummified remains (Egyptians, Peruvians, Unangan hunter-gatherers) documented definite atherosclerosis in 34% of ancient humans.

Pre-industrial humans were not immune.

The Supplement Fluffy LDL Claim



Mendelian randomization shows that altering LDL particle size without changing LDL-C proves size is irrelevant.

Large LDL particles are highly atherogenic; their size does not prevent subendothelial retention.

The Teicholz/Taubes Epidemiology is Flawed Claim

Completely backward-looking. Even if early observational epidemiology was flawed, decades of subsequent MR, statin, PCSK9, and ezetimibe trials provide causal proof immune to those epidemiological criticisms.

Organized Denialism and the J-Curve Fallacy



The THINCS Network

A coordinated group of physicians asserting cholesterol lowering provides no benefit and may be protective in the elderly.

The Fallacy of Reverse Causation

Skeptics cite observational studies showing low LDL-C correlates with higher all-cause mortality in the elderly. This ignores that in frail populations, liver dysfunction, malignancy, and chronic inflammation artificially lower LDL-C.

The Proof

When “leave-one-out” analyses exclude early deaths, or when Mendelian randomization is applied, the ‘protective’ association of high LDL-C disappears entirely.

The “Cholesterol Is Vital” Non-Sequitur

Intracellular Biology (Regulated)



Extracellular Pathology (Atherosclerosis)



The Argument: Skeptics invoke cholesterol’s role in cell membranes and hormones to imply elevated plasma levels are benign.

The Reality: A biological truism applied to the wrong physiological space. Intracellular cholesterol biosynthesis is exquisitely regulated. ASCVD is driven by extracellular, macromolecular ApoB particles breaching the arterial wall. Neonates and primates maintain LDL-C at 40-70 mg/dL with perfect physiological function.

The Alternative Medicine Irony: Practitioners denounce statins as toxic, then prescribe “natural” Red Yeast Rice—which contains Monacolin K, the chemically identical molecule to the statin drug Lovastatin.

Atherosclerosis is a disease of cumulative exposure.



The Bogalusa Evidence:

Autopsy data from the Bogalusa Heart Study and CARDIA show that aortic fatty streaks and fibrous plaques begin forming in the second decade of life.

The Mechanism:

The atherosclerotic clock begins in childhood. Plaque development is a strict mathematical function of "ApoB-years" (ApoB concentration × time).

The Evolutionary Threshold Model of Disease.



The Synthesis: Atherosclerosis is not an inevitable disease of aging, nor a primary disease of inflammation. It requires a sufficient concentration of atherogenic lipoproiteins over time. Maintain lifetime ApoB below 50-60 mg/dL, and subendothelial entrapment becomes functionally negligible.

The Preponderance of Evidence.

The scientific consensus is not genuinely uncertain. The argument that ApoB is irrelevant to ASCVD is a commercially motivated claim that has **failed every empirical test**. The paradigm is clear: lower is better, and lower for longer is best.

Falsification Criteria:

1. **Identify a population with high lifetime ApoB (>100 mg/dL sustained for decades) that develops zero coronary artery calcium by age 80.**
2. **Conduct a 5-year randomized trial where substantial ApoB-particle reduction fails to yield a proportional cardiovascular benefit.**

Until then, ApoB remains the absolute arbiter of atherogenic risk.